Would you like to take some more ruxolitinib after your fedratinib?

被引：0
|
作者：
Ianotto, Jean-Christophe [1 ]
机构：
[1] Univ Hosp Brest, Inst Oncol & Haematol, Dept Haematol, Bld Tanguy Prigent, F-29609 Brest, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年
关键词：
fedratinib; myelofibrosis; ruxolitinib; SINGLE-ARM; OPEN-LABEL; MYELOFIBROSIS; EFFICACY; SAFETY; PHASE;
D O I：
10.1111/bjh.19695
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In Europe, ruxolitinib and fedratinib are the only JAK2 inhibitors available in local pharmacies. According to trial data, myelofibrosis patients should mostly receive ruxolitinib as first-line treatment and fedratinib in case of failure or intolerance (depending on their profile). Is it possible to reverse the choice of these drugs? Commentary on: Palandri et al. Ruxolitinib after Fedratinib failure in patients with myelofibrosis: a real-world case series. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/ bjh.19654.
引用
收藏
页数：2
相关论文
共 50 条
12345